Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | AGXT | P21549 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007285 | 0.85 | LOXL2 (0.48) | LOXL2TAAR1IDO1AGXTABAT | |
| SCHEMBL522479 | 0.85 | EGFR (0.43) | CYP4F2CYP4A11KIF11EGFRSLC6A2 | |
| SCHEMBL28061149 | 0.84 | KDM4E (0.44) | LOXL2TAAR1SLC6A2CA2 | |
| SCHEMBL2386178 | 0.83 | CYP4F2 (0.43) | CYP4F2CYP4A11LOXL2KIF11TAAR1 | |
| SCHEMBL18562850 | 0.83 | LOXL2 (0.43) | LOXL2TAAR1IDO1AGXTABAT | |
| SCHEMBL6563067 | 0.81 | TAAR1 (0.52) | TAAR1SLC6A2 | |
| SCHEMBL23199297 | 0.80 | EGFR (0.39) | LOXL2EGFRCA2ABATPRSS1 | |
| SCHEMBL2389571 | 0.79 | TAAR1 (0.45) | LOXL2KIF11TAAR1IDO1AGXT | |
| SCHEMBL14491132 | 0.79 | CYP4F2 (0.47) | CYP4F2CYP4A11KIF11EGFRSLC6A2 | |
| Hydrochloric Acid SCHEMBL6563097 | 0.79 | TAAR1 (0.50) | TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-11807620-B2 | Quinazolinone compounds and related compounds | Plexium, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-102099344-B | Imidazole carboxamides | LILLY CO ELI | 2013-10-30 | — | — | CN | disclosed |
| EP-2318375-B1 | IMIDAZOLE CARBOXAMIDES | LILLY CO ELI (US) | 2012-09-19 | — | — | EP | disclosed |
| CN-102099344-A | Imidazole carboxamides | LILLY CO ELI | 2011-06-15 | — | — | CN | disclosed |
| US-7754742-B2 | Imidazole carboxamides | ELI LILLY AND COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| CN-1471512-A | Geminally substituted alphavβ3Integrin antagonists | — | 2004-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016373-A1 | IMIDAZOLE CARBOXAMIDES | CYP3A4, CYP2C9, AADAC | CYP4F2 305/4885CYP4A11 173/4885LOXL2 4786/4885 |
| US-11807620-B2 | Quinazolinone compounds and related compounds | NQO2, COQ8A, PARK7 | CYP4F2 699/4885CYP4A11 1630/4885LOXL2 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.